CAR-NK cell therapy against multiple refractory solid tumors targeting mucin 1 (MUC1), including pancreatic tumors, HCC, NSCLC and triple-negative invasive breast tumors, is also under investigation in clinical trials (NCT02839954). Here, MUC1 is linked to hepatocellular carcinoma.